Augustine Therapeutics is a biotechnology company developing therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases through selective inhibition of the HDAC6 enzyme.

Callio Therapeutics develops multi-payload antibody-drug conjugates for cancer therapy.

XyloCor Therapeutics develops gene therapies for cardiovascular diseases, focusing on treatments for refractory angina and coronary artery bypass graft surgery.

Aviceda Therapeutics is a biotech company developing next-generation immunomodulators for ophthalmic conditions using its proprietary HALOS™ nanotechnology platform.

Alentis Therapeutics is a biotech company developing antibody-drug conjugates for treating Claudin-1 positive tumors and organ fibrosis.

NMD Pharma is a biotech company focused on developing small molecule therapies for neuromuscular diseases by targeting the skeletal muscle chloride ion channel (ClC-1).

EyeBio is a clinical-stage ophthalmology biotechnology company focused on developing therapies for sight-threatening eye diseases and has expanded its Series A funding to $130 million.

Corteria Pharmaceuticals is a biopharmaceutical company that develops first-in-class therapies for unaddressed heart failure subpopulations, with a focus on multi-organ benefits targeting the kidneys, heart, and vessels.